On May 8, 2018 Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, reported that on May 15, 2018, the Company will release its financial results for the quarter ended March 31, 2018 (Press release, Affimed,MAY 8, 2018, View Source [SID1234526279]). The Company’s management team will host a conference call to discuss the Company’s financial results and recent corporate developments on Tuesday, May 15, 2018 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 3326332.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
United States: +1 720-543-0214
Germany: +49 (0)89 20303 5709
Netherlands: +31 (0) 20 721 9251
Denmark: +45 35 15 80 49
France: +33 (0)1 76 77 22 74
Switzerland: +41 (0)22 567 5729
United Kingdom: +44 (0)330 336 9105
An audio webcast of the conference call can be accessed in the "Events" section on the "Investors & Media"
page of the Affimed website at View Source A replay of the webcast will be
available on Affimed’s website shortly after the conclusion of the call and will be archived on the Affimed
website for 30 days following the call.